Fluticasone propionate,a new type of glucocorticoid developed by Glaxosmithkline in the United Kingdom,has strong efficacy and weak adverse reactions compared with other glucocorticoid drugs.
Cancer is one leading cause of morbidity and mortality nowadays,whereas targeted small molecules including protein kinase inhibitors and others are important drugs to treat cancers.
Indoleamine 2,3-dioxygenase 1(IDO1)and tryptophan 2,3-dioxygenase(TDO)are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions[1].